A hormonal association between estrogen metabolism and proliferative thyroid disease

被引:18
|
作者
Chan, EK
Sepkovic, DW
Bowne, HJY
Yu, GP
Schantz, SP
机构
[1] New York Eye & Ear Infirm, New York Med Coll, Dept Otolaryngol Head & Neck Surg, New York, NY 10003 USA
[2] Hackensack Univ, Med Ctr, Hackensack, NJ 07601 USA
[3] New York Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, New York, NY USA
[4] New York Eye & Ear Infirm, St Vincents Hosp Manhattan, New York, NY USA
关键词
D O I
10.1016/j.otohns.2006.01.020
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
OBJECTIVE: To illustrate a relationship between proliferative thyroid disease and estrogen metabolism through the analysis of urinary estrogen metabolites. STUDY DESIGN AND SETTING: Case-control study of 49 subjects with proliferative thyroid disorders and matching them to 49 controls. Urinary estrogen metabolite ratios were obtained, measuring 2-hydroxyestrone, an anti-proliferative metabolite, to 16 alpha-hydroxyestrone, a proliferative metabolite. The patients were stratified into low (0 to 1.00), medium (1.01 to 2.00), or high (> 2.00) groups according to their estrogen metabolite ratio. RESULTS: Fifty-one percent (25 of 49) of the cases had a low 2/16 ratio compared to 31% (15 of 49) in the control group while 20% (10 of 49) of the control group had a high 2/16 ratio as compared to 8% (4 of 49) in the case group (P value < 0.05). CONCLUSIONS: increased 16 alpha-hydroxyestrone activity compared to 2-hydroxyestrone activity appears to be associated with proliferative thyroid disease. SIGNIFICANCE: Further study of estrogen metabolites in relation to proliferative thyroid disease is warranted and may lead to implications for new treatment modalities for proliferative thyroid disease.
引用
收藏
页码:893 / 900
页数:8
相关论文
共 50 条
  • [41] THE ASSOCIATION BETWEEN ALZHEIMERS-DISEASE AND THYROID-DISEASE IN ROCHESTER, MINNESOTA
    YOSHIMASU, F
    KOKMEN, E
    HAY, ID
    BEARD, CM
    OFFORD, KP
    KURLAND, LT
    NEUROLOGY, 1991, 41 (11) : 1745 - 1747
  • [42] ASSOCIATION BETWEEN CELIAC-DISEASE AND AUTOIMMUNE THYROID-DISEASE - REPLY
    COLLIN, P
    REUNALA, T
    PASTERNACK, A
    GUT, 1995, 36 (03) : 476 - 476
  • [43] TRIGLYCERIDE METABOLISM IN THYROID DISEASE
    TULLOCH, BR
    LEWIS, B
    FRASER, TR
    LANCET, 1973, 1 (7800): : 391 - 394
  • [44] TRIGLYCERIDE METABOLISM IN THYROID DISEASE
    SANDERSON, C
    LANCET, 1973, 1 (7802): : 547 - 547
  • [45] TRIGLYCERIDE METABOLISM IN THYROID DISEASE
    TULLOCH, BR
    VYDELINGUM, N
    LEWIS, B
    FRASER, R
    CLINICAL SCIENCE, 1973, 44 (02) : P6 - P6
  • [46] DIGOXIN METABOLISM IN THYROID DISEASE
    CROXSON, MS
    YOUNG, MR
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1973, 3 (02): : 217 - 217
  • [47] Possible interplay between estrogen and the BAFF may modify thyroid activity in Graves' disease
    Cheng, Chao-Wen
    Fang, Wen-Fang
    Tang, Kam-Tsun
    Lin, Jiunn-Diann
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [48] Possible interplay between estrogen and the BAFF may modify thyroid activity in Graves’ disease
    Chao-Wen Cheng
    Wen-Fang Fang
    Kam-Tsun Tang
    Jiunn-Diann Lin
    Scientific Reports, 11
  • [49] Association between HER2 oncoprotein and hormonal receptors (estrogen receptor and progesterone receptor) on breast cancer
    Fulkiadli, F.
    Khambri, D.
    Harahap, W.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Estrogen plus progestin and risk of benign proliferative breast disease
    Rohan, Thomas E.
    Negassa, Abdissa
    Chlebowski, Rowan T.
    Lasser, Norman L.
    McTiernan, Anne
    Schenken, Robert S.
    Ginsberg, Mindy
    Wassertheil-Smoller, Sylvia
    Page, David L.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2008, 17 (09) : 2337 - 2343